Boston gains green-light for pivotal stent trial:
This article was originally published in Clinica
Boston Scientific has begun a pivotal trial of its paclitaxel-coated stent in the US, after gaining go-ahead from the FDA. The prospective, randomised, double-blind TAXUS IV trial, which will involve over 1000 patients at 80 sites, will assess the safety and efficacy of a slow-release formulation of the drug-eluting stent as a treatment for coronary restenosis. The trial data will form the basis for a marketing application in the US.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.